title: Remission induction therapy: the more intensive the better?
abstract: Intensive induction therapy in acute myeloid leukemia (AML) as in some other systemic malignancies is a strategy fundamentally different from post-remission strategies. Approaches such as consolidation treatment, prolonged maintenance, and autologous or allogeneic transplantation in first remission are directed against the minimal residual disease in which a malignant cell population has survived induction treatment and shows resistance due to special genetic or kinetic features. In contrast, induction therapy deals with naive tumor cells possibly different from their counterparts in remission in terms of their kinetic status and sensitivity. Therefore, in AML the introduction of intensification strategies into the induction phase of treatment has been suggested as a new step in addition to intensification in the postremission phase. As expected from the dose effects observed in post-remission treatment with high-dose cytarabine (AraC) or longer treatment, similar dose effects have been found in induction treatment both from the incorporation of high-dose AraC and from the double-induction strategy used in patients up to 60 years of age. As a particular effect, patients with poor-risk AML according to an unfavorable karyotype, high LDH in serum, or a delayed response show longer survival following double induction containing high-dose AraC as compared to standard-dose AraC. A corresponding dose effect in the induction treatment of patients aged 60 years and older has been found with daunorubicin 60 vs 30 mg/m2 as part of the thioguanine/ AraC/daunorubicin (TAD) regimen with the higher dosage significantly increasing the response rate and survival in these older patients who represent a poor-risk group as a whole. Thus we have been able to demonstrate both in younger and older patients that a poor prognosis can be improved by a more intensive induction therapy. High-dose AraC in induction, however, exhibits cumulative toxicity in that repeated courses containing high-dose AraC in the post-remission period lead to long-lasting aplasias of about 6 weeks. Thus after intensive induction treatment, high-dose chemotherapy in remission may be practicable using stem-cell rescue and may contribute to a further improvement in the outcome in poor-risk as well as average-risk patients with AML. These approaches are currently under investigation by the German AML Cooperative Group (AMLCG). "The more intensive the better" is certainly not the way to go in the management of AML and other systemic malignancies but some increase in intensity may be possible and better.
authors.affiliation: Department of Medicine, Hematology/Oncology, University of Münster, Germany. buechnr@uni-muenster.de
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: W
authors.initials: W
authors.lastname: Berdel
authors.forename: B
authors.initials: B
authors.lastname: Wörmann
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: C
authors.initials: C
authors.lastname: Schoch
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: P
authors.initials: P
authors.lastname: Staib
authors.forename: R
authors.initials: R
authors.lastname: Andreesen
authors.forename: L
authors.initials: L
authors.lastname: Balleisen
authors.forename: D
authors.initials: D
authors.lastname: Haase
authors.forename: H
authors.initials: H
authors.lastname: Eimermacher
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: H
authors.initials: H
authors.lastname: Rasche
authors.forename: J
authors.initials: J
authors.lastname: Uhlig
authors.forename: A
authors.initials: A
authors.lastname: Grüneisen
authors.forename: H E
authors.initials: HE
authors.lastname: Reis
authors.forename: J
authors.initials: J
authors.lastname: Hartlapp
authors.forename: W D
authors.initials: WD
authors.lastname: Hirschmann
authors.forename: H J
authors.initials: HJ
authors.lastname: Weh
authors.forename: H J
authors.initials: HJ
authors.lastname: Pielken
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: M C
authors.initials: MC
authors.lastname: Sauerland
authors.forename: A
authors.initials: A
authors.lastname: Heinecke
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin